论文部分内容阅读
目的观察恩度(YH-16)联合伽玛刀治疗老年局部晚期非小细胞肺癌(NSCLC)的近远期疗效和不良反应。方法将67例患者随机分为两组,试验组(34例)采用恩度联合伽玛刀治疗;对照组(33例)采用单独伽玛刀治疗。按WHO标准评价疗效,比较近期有效率、临床受益率、不良反应、中位无进展生存时间、1年生存率、2年生存率。结果试验组和对照组近期总有效率分别为61.7%和48.5%(P>0.05),临床受益率分别为94.1%和87.8%(P>0.05),两组比较差异无统计学意义;而中位无进展生存时间分别为18.7个月和11.2个月,1年生存率分别为71.4%和45.1%,2年生存率分别为36.3%和15.2%,两组比较差异有统计学意义。结论恩度联合伽玛刀治疗能提高老年局部晚期非小细胞肺癌的远期疗效,且不良反应可以耐受。
Objective To observe the long-term and long-term efficacy and adverse reactions of YH-16 combined with gamma knife in the treatment of elderly patients with locally advanced non-small cell lung cancer (NSCLC). Methods Sixty-seven patients were randomly divided into two groups. The experimental group (34 cases) was treated with Endo-associated gamma knife; the control group (33 cases) was treated with a separate gamma knife. Efficacy was evaluated according to WHO criteria, and recent efficacy, clinical benefit rate, adverse reactions, median progression-free survival time, 1-year survival rate, and 2-year survival rate were compared. Results The total effective rates of the trial group and the control group were 61.7% and 48.5% (P>0.05), and the clinical benefit rates were 94.1% and 87.8%, respectively (P>0.05). There was no significant difference between the two groups; The progression-free survival time was 18.7 months and 11.2 months, respectively. The 1-year survival rates were 71.4% and 45.1%, and the 2-year survival rates were 36.3% and 15.2%, respectively. There was a statistically significant difference between the two groups. Conclusion Endotherapy combined with gamma knife treatment can improve the long-term efficacy of elderly patients with locally advanced non-small cell lung cancer, and the adverse reactions can be tolerated.